Comparison
Two Russian-lineage peptides that share a longevity-and-sleep audience and a seat on FDA's 2026 compounding agenda.
Epitalon is the longevity-framed tetrapeptide built on telomerase and melatonin-rhythm claims; DSIP is the older sleep-framed nonapeptide whose human literature is small, old, and inconsistent.
Epitalon's claims center on telomerase activation and melatonin rhythm restoration, mostly from the Khavinson research lineage. DSIP was named for a sleep effect in 1970s rabbit work and accumulated decades of small, inconsistent human sleep studies.
Neither is strong. Epitalon's support is in-vitro telomerase work plus small aging-population studies from one lineage; DSIP has a handful of old double-blind sleep studies with mixed results. Both are best described as unproven.
Both appear on FDA's July 2026 Pharmacy Compounding Advisory Committee agenda (DSIP as emideltide), meaning compounded access to both could change with the committee's recommendation.
| Dimension | Epitalon | DSIP |
|---|---|---|
| Overall evidence grade | D | D |
| Evidence label | Mostly preclinical | Limited human evidence |
| Regulatory status | Investigational / not approved | Investigational / not approved |
| Editorial confidence | Low confidence | Low confidence |
| Efficacy | 1/5 limited | 0/5 not mapped |
| Safety | 1/5 limited | 1/5 limited |
| Regulatory risk | 4/5 high | 4/5 high |
| Product quality risk | 5/5 very high | 5/5 very high |
| Primary claim categories | Longevity claims, Sleep and circadian claims, Cellular aging claims | Sleep claims, Insomnia claims, Opioid-withdrawal claims, Recovery claims |
Epitalon has mechanism and review sources, but clinical longevity and sleep benefits have not been shown in outcome trials.
DSIP has older sleep-study history, but that history does not automatically support personal-use, opioid-withdrawal, narcolepsy, or recovery claims.
PubMed. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells 2003.
PMID:12937682 Accessed 2026-06-08.
Human somatic cell source for telomerase/telomere mechanism; not a clinical longevity outcome.
PubMed. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people 2007.
PMID:17969590 Accessed 2026-06-09.
Older human and non-human primate melatonin-rhythm source naming Epitalon/AEDG; biomarker context, not sleep efficacy or use guidance.
PubMed. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study 1992.
PMID:1299794 Accessed 2026-06-08.
Older human insomnia study; keep study context separate from protocol advice.
PubMed. Delta sleep-inducing peptide (DSIP): a still unresolved riddle 2006.
PMID:16539679 Accessed 2026-06-08.
Review emphasizing unresolved DSIP biology.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.